Novartis acquisition of Morphosys receives approval from Germany
Published: Tuesday, Mar 12th 2024, 11:30
Updated At: Tuesday, Mar 12th 2024, 11:50
العودة إلى البث المباشر
قد تستحوذ نوفارتيس على شركة مورفوسيس الألمانية للتكنولوجيا الحيوية. أعطى مكتب الكارتل الألماني الضوء الأخضر لعملية الشراء يوم الثلاثاء.
"We have examined very carefully that competition in the research and development of new drugs against a form of leukemia will not be impaired by the merger. As a result, we have no serious competition concerns," explained Andreas Mundt, President of the German Federal Cartel Office, in a press release.
أعلنت شركة Novartis عن نيتها شراء Morphosys في بداية شهر فبراير وتعتزم دفع 68.00 يورو للسهم الواحد. وبذلك يصل سعر الشراء إلى 2.7 مليار يورو.
The transaction gives Novartis access to pelabresib, a drug for the treatment of myelofibrosis (MF), a life-threatening chronic disease of the bone marrow. In a recent combination study, the active ingredient led to a reduction in spleen volume and thus achieved the targets set. In the USA, the application for approval from the US Food and Drug Administration (FDA) should be submitted in the second half of 2024 if possible.
©كيستون/إسدا
Arabic 
English 
German 
French 
Spanish